文献速递妇科肿瘤

奥拉帕利对比非铂化疗治疗铂敏感复发性卵巢癌患者:III期SOLO3研究最终总生存结果

Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.
PubMed 文献 · J Clin Oncol · 2024-12-12

在开放标签III期SOLO3试验中,BRCA突变铂敏感复发性卵巢癌患者随机2:1接受奥拉帕利片剂(300mg每日两次,n=178)或医生选择的单药非铂化疗(n=88)。最终总生存分析显示奥拉帕利组与化疗组相似(HR 1.07,95%CI 0.76-1.49,P=0.71,中位34.9个月对32.9个月)。既往2线化疗患者奥拉帕利组OS有利(HR 0.83),但≥3线患者可能有害(HR 1.33),BRCA回复突变可能参与其中。

要点

  • 奥拉帕利组与化疗组总生存相似:HR 1.07(95%CI 0.76-1.49),P=0.71,中位34.9对32.9个月。
  • 既往2线化疗患者奥拉帕利组OS有利:HR 0.83(95%CI 0.51-1.38),中位37.9对28.8个月。
  • 既往≥3线化疗患者奥拉帕利组可能有害:HR 1.33(95%CI 0.84-2.18),中位29.9对39.4个月。

核心结论

  • 在BRCA突变铂敏感复发性卵巢癌中,奥拉帕利对比非铂化疗的最终总生存无显著差异(HR 1.07,95%CI 0.76-1.49,P=0.71)。
  • 既往2线化疗患者奥拉帕利组OS有利(HR 0.83,95%CI 0.51-1.38),但既往≥3线化疗患者可能有害(HR 1.33,95%CI 0.84-2.18)。
  • BRCA回复突变可能解释上述发现。

研究设计与样本

  • 开放标签III期SOLO3试验(ClinicalTrials.gov标识NCT02282020)。
  • 266例患者随机2:1分配至奥拉帕利片剂300mg每日两次(n=178)或医生选择的单药非铂化疗(聚乙二醇脂质体多柔比星、紫杉醇、吉西他滨或拓扑替康;n=88)。
  • 本报告为最终总生存(预设次要终点)、按既往化疗线数的post hoc OS分析及探索性BRCA回复突变分析。

主要发现

  • 总生存奥拉帕利组对比化疗组:HR 1.07(95%CI 0.76-1.49),P=0.71,中位34.9对32.9个月(全分析集)。
  • 既往2线化疗患者OS:奥拉帕利组对比化疗组HR 0.83(95%CI 0.51-1.38),中位37.9对28.8个月。
  • 既往≥3线化疗患者OS:奥拉帕利组对比化疗组HR 1.33(95%CI 0.84-2.18),中位29.9对39.4个月。
  • 基线检出BRCA回复突变者6/170(3.5%),随机分配至奥拉帕利且基线检出BRCA回复突变的患者中无一例达到客观肿瘤缓解。

关键数值与推荐

  • 奥拉帕利片剂300mg每日两次。
  • 非铂化疗可选聚乙二醇脂质体多柔比星、紫杉醇、吉西他滨或拓扑替康单药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • OS按既往化疗线数的分析为post hoc分析。
  • BRCA回复突变分析为探索性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Olaparib treatment significantly improved objective response rate (primary end point) and progression-free survival versus nonplatinum chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer in the open-label phase III SOLO3 trial (ClinicalTrials.gov identifier: NCT02282020). We report final overall survival (OS; prespecified secondary end point), post hoc OS analysis by number of previous chemotherapy lines, and exploratory BRCA reversion mutation analysis. Two hundred sixty-six patients were randomly assigned 2:1 to olaparib tablets (300 mg twice daily; n = 178) or physician's choice of single-agent nonplatinum chemotherapy (pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan; n = 88). OS was similar with olaparib versus chemotherapy (hazard ratio [HR], 1.07 [95% CI, 0.76 to 1.49]; P = .71, median 34.9 and 32.9 months, respectively, full analysis set). OS with olaparib was favorable in patients with two previous chemotherapy lines (HR, 0.83 [olaparib v chemotherapy] [95% CI, 0.51 to 1.38]; median 37.9 v 28.8 months); however, a potential detrimental effect was seen in patients with at least three previous chemotherapy lines (HR, 1.33 [95% CI, 0.84 to 2.18]; median 29.9 v 39.4 months). BRCA reversion mutations might have contributed to this finding. No patient randomly assigned to olaparib with a BRCA reversion mutation detected at baseline (6 of 170 [3.5%]) achieved an objective tumor response.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Scambia G, Villalobos Valencia R, Colombo N, et al. Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results. J Clin Oncol. 2024. PMID: 39668137. doi:10.1200/JCO.24.00933

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。